metricas
covid
Buscar en
Clinics
Toda la web
Inicio Clinics Safety and efficacy of short-term dual antiplatelet therapy combined with intens...
Información de la revista
Vol. 78.
(enero - diciembre 2023)
Compartir
Compartir
Descargar PDF
Más opciones de artículo
Visitas
1136
Vol. 78.
(enero - diciembre 2023)
Original articles
Acceso a texto completo
Safety and efficacy of short-term dual antiplatelet therapy combined with intensive rosuvastatin in acute ischemic stroke
Visitas
1136
Ting Denga, Wei Hea, Xiaohua Yaoa, Jingmian Chena, Xiaomeng Liua, Lushan Liua, Tong Zhangb,
Autor para correspondencia
tommzhang@163.com

Corresponding author.
, Haitao Lub,
Autor para correspondencia
13051760807@163.com

Corresponding author.
a Emergency Department, China Rehabilitation Research Center Beijing Bo'ai Hospital, Beijing, China
b Neurology Department, China Rehabilitation Research Center Beijing Bo'ai Hospital, Beijing, China
Este artículo ha recibido
Información del artículo
Resumen
Texto completo
Bibliografía
Descargar PDF
Estadísticas
Figuras (3)
Mostrar másMostrar menos
Tablas (5)
Table 1. Baseline characteristics of the patientsa.
Table 2. Comparison of NIHSS scores between the two groups before and 21 days after treatment.
Table 3. Comparison of the trend of NHISS scores in the two groups within 21 days.
Table 4. Comparison of recurrent ischemic stroke between two groups.
Table 5. Comparison of ALT, AST, LDH and CK before and 2 weeks after treatment.
Mostrar másMostrar menos
ABSTRACT
Objective

To investigate the safety and efficacy of short-term (7-day) Dual Antiplatelet Therapy (DAPT) with intensive rosuvastatin in Acute Ischemic Stroke (AIS).

Methods

In this study, patients with AIS in the emergency department of the hospital from October 2016 to December 2019 were registered and divided into the control group (Single Antiplatelet Therapy [SAPT] + rosuvastatin) and the study group (7-day DAPT + intensive rosuvastatin) according to the therapy regimens. The generalized linear model was used to compare the National Institute of Health Stroke Scale (NIHSS) scores between the two groups during the 21-day treatment. A Cox regression model was used to compare recurrent ischemic stroke, bleeding events, Statin-Induced Liver Injury (SILI), and Statin-Associated Myopathy (SAM) between the two groups during the 90-day follow-up.

Results

Comparison of NIHSS scores after 21-day treatment: NIHSS scores in the study group decreased significantly, 0.273-times as much as that in the control group (Odds Ratio [OR] 0.273; 95% Confidence Interval [95% CI] 0.208–0.359; p < 0.001). Comparison of recurrent ischemic stroke during the 90-day follow-up: The therapy of the study group reduced the risk of recurrent stroke by 65% (7.76% vs. 22.82%, Hazard Ratio [HR] 0.350; 95% CI 0.167–0.730; p = 0.005). Comparison of bleeding events: There was no statistical difference between the two groups (7.79% vs. 6.71%, HR = 1.076; 95% CI 0.424–2.732; p = 0.878). No cases of SILI and SAM were found.

Conclusions

Short-term DAPT with intensive rosuvastatin effectively relieved the clinical symptoms and significantly reduced the recurrent stroke for patients with mild-to-moderate AIS within 90 days, without increasing bleeding events, SILI and SAM.

Keywords:
Short-Term Dual Antiplatelet Therapy
Single Antiplatelet Therapy
Intensive Rosuvastatin
Recurrent Ischemic Stroke
Abbreviations:
AIS
DAPT
TIA
SAPT
CT
MRI
NIHSS
bNIHSS
OMT
GUSTO
SILI
SAM
ALT
AST
CK
LDH
IQR
SBP
DBP
ASCVD
eNOS
Texto completo
Introduction

Stroke is a major chronic non-communicable disease that is a serious health threat among Chinese people and is the leading cause of death and disability in adults in China.1 China has the highest number of stroke patients in the world.2 Among them, ischemic stroke accounts for 85% of all stroke, and its annual recurrence rate is as high as 5.6%,3 which has caused huge psychological pressure and economic burden to society and families.2 Prevention and treatment of stroke and reduction of its recurrence have become the most important topic in the field of stroke. Recently, great progress has been made in endovascular therapy, including intravenous thrombolysis and arterial thrombolysis,4,5 but most patients miss the optimal time window for treatment. The antiplatelet aggregation has become the most routine regimen for acute treatment and secondary prevention for Acute Ischemic Stroke (AIS).2

The CHANCE6 study initiated Dual Antiplatelet Therapy (DAPT) for AIS in China, which reduced the risk of recurrent ischemic stroke within 90 days and increased the risk of bleeding events7,8 in patients with minor AIS or high-risk Transient Ischemic Attack (TIA), in particular, the risk of bleeding was significantly increased after 1 week of treatment.9 To explore a more accurate DAPT regimen for AIS, the authors compared the safety and efficacy of short-term (7-day) DAPT+intensive rosuvastatin & Single Antiplatelet Therapy (SAPT)+rosuvastatin in patients with mild-to-moderate AIS.

Materials and methodsPatients

The authors registered patients with AIS admitted to the emergency department of the hospital from October 2016 to December 2019, and their diagnosis met the 2018 criteria of the Chinese Guidelines for Diagnosis and Treatment of Acute Ischemic Stroke.10 The study was approved by the Medical Ethics Committee of the hospital (No. 2018-022-1). The patients themselves or their legal proxies were informed of the study details, and their written consent was obtained.

Inclusion criteria: 1) Age ≥18 years; 2) Head Computed Tomography (CT) and brain Magnetic Resonance Imaging (MRI) showing new infarction lesion; 3) Definite symptoms of focal neurological deficit, and the baseline scores of National Institutes of Health Stroke Scale (bNIHSS) at registration ≤10; 4) Time of Onset to Medication (OMT) ≤ 72h.

Exclusion criteria: 1) Patients with intravenous thrombolysis/arterial thrombectomy; 2) Patients with tumors or severe functional impairment of other organs; 3) Patients on anticoagulant medication; 4) Menstruating and/or pregnant women and those planning to conceive within 3-months.

Removal Criteria: to ensure that National Institutes of Health Stroke Scale (NIHSS) scores are not affected by physical function, the authors further ruled out: 1) Age ≥ 80 years, and bNIHSS ≤ 3; 2) 70 years ≤ age < 80 years, and bNIHSS ≤ 2; 3) Age ≤ 60 years, and bNIHSS = 1; and 4) Incomplete data.

Treatment and grouping regimens

The patients enrolled in this study were divided into a study group and a control group according to the therapy regimens. The therapy regimen for the study group was 7-day DAPT+intensive rosuvastatin, while that for the control group was SAPT + rosuvastatin. The specific regimen is as described below:

Study group: aspirin (BayerHealthCareManufacturingS.r.l.) 100 mg/d with an initial dose 300 mg for 90 days, clopidogrel (SanofiClirSNC) 75 mg/d with an initial dose 75–300 mg according to patients’ symptoms for 7 days, and rosuvastatin (Nanjing Chia Tai-Tianqing Pharmaceutical Co., Ltd.) 20 mg/d for 21 days, followed by 10 mg/d until the 90th day.

Control group: aspirin 100 mg/d or clopidogrel 75 mg/d for 90 days, and rosuvastatin 10 mg/d for 90 days.

The basic treatments for the two groups were the same. Both groups were followed-up for 90 days.

Assessment of results

Clinical efficacy: NIHSS was used to evaluate the severity of neurological deficit symptoms of AIS patients at seven-time points before treatment (T0), and 12h (T1), 24h (T2), 48h (T3), 1 week (T4), 2 weeks (T5), and 3 weeks (T6) after treatment. The score ranged from 0 to 43, with a higher score indicating more severe disease. Scores of ≤ 4, 5–14, and > 15, respectively, indicated mild, moderate, and severe AIS.11 Because there were few patients with severe AIS in the emergency department of the studied hospital, and most of them needed intravenous thrombolysis or arterial thrombectomy, only patients with bNIHSS ≤ 10 were registered in this study.

Recurrent ischemic stroke was identified in patients with AIS had another ischemic stroke within the 90-day follow-up, and brain MRI showed a new infarct or the original infarct was significantly enlarged. Regarding bleeding events, patients with AIS had bleeding events within 90 days after treatment, including intracranial hemorrhage verified by head CT, or gastrointestinal or mucocutaneous bleeding verified by a positive occult blood test. Mild, moderate, or severe bleeding was defined according to the Global Use of Streptokinase and Tissue plasminogen activator to treat coronary Occlusion (GUSTO).12 Statin-Induced Liver Injury (SILI) was defined when the level of Alanine Aminotransferase (ALT) or Aspartate Aminotransferase (AST) increased to ≥ 3 times higher than normal during the use of statins.13 Statin-Associated Myopathy (SAM) was defined when the level of Creatine Kinase (CK) rose ≥ 3 (3–10) times higher than normal during the use of statins.14

Data collection

The general clinical data; medical history (hypertension, diabetes, hyperlipidemia, atrial fibrillation, prior ischemic stroke, prior antiplatelet); smoking; drinking; OMT; and NIHSS scores at seven different time points were recorded. Laboratory items included serum levels of ALT, AST, Lactate Dehydrogenase (LDH), and CK before and 2 weeks (14 ± 3 days) after treatment. Recurrent ischemic stroke events, bleeding events, and SILI and SAM events within 90 days of follow-up were recorded.

Statistical analysis

SPSS 25.0 statistical software (IBM Corporation, Armonk, NY, USA) was used for data analysis: 1) Because the continuous data of the baseline characteristics of the two groups of patients did not conform to the normal distribution, they were expressed as median (Interquartile Range [IQR]) and were tested using the rank sum test. Categorical data were expressed as (%) and were tested using the chi-square method. 2) The generalized linear model was used to analyze the changing trend of the NIHSS scores at seven different time points. 3) A Cox proportional hazard model was used to compare the difference between recurrent ischemic stroke events and bleeding events within 90 days between the two groups; p < 0.05 was considered to indicate statistically significant differences.

ResultsComparison of baseline data and the levels of ALT, AST, LDH, and CK between the two groups

A total of 265 patients were enrolled in this study: 149 patients in the control group and 116 patients in the study group. There was no significant difference between the two groups in terms of age; sex; Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) at registration; OMT; bNIHSS; medical history; and levels of ALT, AST, LDH, and CK before and 2 weeks (14 ± 3 days) after treatment (p > 0.05) (Table 1).

Table 1.

Baseline characteristics of the patientsa.

Characteristics  Control group (n = 149)  Study group (n = 116)  p-value 
Median age (IQR), years  65.00 (58.50‒77.00)  65.00 (58.25‒74.50)  0.843 
Female, n (%)  48 (32.2)  26 (22.4)  0.097 
Median SBP (IQR), mm/Hg  154.00 (138.00‒174.00)  153.00 (142.25‒172.00)  0.887 
Median DBP (IQR), mm/Hg  89.00 (78.00‒103.00)  90.00 (81.00‒103.00)  0.221 
Medical history, n (%)       
Hypertension  129 (86.6)  95 (81.9)  0.309 
Diabetes  64 (43.0)  46 (39.7)  0.617 
Known atrial fibrillation  23 (15.4)  11(9.5)  0.195 
Ischemic stroke  66 (44.3)  42 (36.2)  0.208 
Antiplatelet  37 (24.8)  31 (26.7)  0.777 
Median OMT (IQR) – hours  12.00 (5.00‒25.00)  18.00 (5.00‒36.00)  0.612 
Median bNIHSS (IQR)  4.00 (2.00‒5.00)  4.00 (3.00‒5.00)  0.151 
Median various enzymology before medication (IQR), U/L       
ALT  17.00 (12.20‒22.00)  18.35 (13.83‒24.53)  0.171 
AST  16.40 (12.25‒22.10)  16.55 (13.00‒21.60)  0.751 
LDH  176.00 (158.00‒200.50)  178.50 (150.50‒202.50)  0.980 
CK  81.00 (55.50‒127.00)  70.00 (53.25‒109.25)  0.103 
Median of various enzymology in 2 weeks after medication (IQR), U/L       
ALT  17.60 (12.05‒25.10)  17.20 (12.65‒25.58)  0.785 
AST  17.00 (13.20‒21.65)  17.70 (14.10‒21.85)  0.569 
LDH  181.00 (156.00‒210.00)  171.50 (151.00‒202.25)  0.056 
CK  71.00 (49.00‒101.50)  68.00 (46.50‒101.50)  0.409 
a

There were no significant differences between the study group and control group for any parameter.

SBP, Systolic Blood Pressure; DBP, Diastolic Blood Pressure; OMT, Time of Onset to Medication; bNIHSS, the baseline scores of National Institutes of Health Stroke Scale at registration; ALT, Alanine Aminotransferase; AST, Aspartate Aminotransferase; LDH, Lactate Dehydrogenase; CK, Creatine Kinase.

Comparison of NIHSS scores between the two groups

The generalized linear model was used to compare the NIHSS scores of the two groups at seven different time points before treatment (T0), and 12h (T1), 24h (T2), 48h (T3), 1 week (T4), 2 weeks (T5), and 3 weeks (T6) after treatment. The results are as follows:

The main effect of the therapy regimens: There was no significant difference in bNIHSS between the two groups (Odds Ratio [OR] 1.186; 95% Confidence Interval [95% CI] 0.592–2.377; p = 0.631). After 21 days of treatment, there was a statistically significant difference between the two groups, and the NIHSS score of the study group was significantly reduced, which was 27.3% of that of the control group (OR = 0.273; 95% CI 0.208–0.359; p < 0.001) (Table 2). Figure 1 was the declining trend curves of the NIHSS scores of the two groups after adjusting for the influence of age and OMT. The curves showed that the NIHSS scores of the study group were significantly lower than that of the control group after 21 days of treatment, suggesting that 7-day DAPT+intensive rosuvastatin effectively alleviated the patient's clinical symptoms.

Table 2.

Comparison of NIHSS scores between the two groups before and 21 days after treatment.

Coefficientp-valueOR95% Confidence Interval
Lower  Upper 
(Intercept)  3.857  0.000  47.330  39.527  56.673 
[study group] * [time = 0]a  0.171  0.631  1.186  0.592  2.377 
[control group] * [time = 0]       
[study group] * [time = 6]b  -1.298  0.000  0.273  0.208  0.359 
[control group] * [time = 6]       
a

Comparison of the bNIHSS between the two groups

b

Comparison of NIHSS scores between the two groups after 21 days of treatment.

Figure 1.

The change trend curve of NIHSS scores of the two groups within 21 days. (NIHSS, National Institutes of Health Stroke Scale at registration).

(0.13MB).

Comparison of NIHSS scores within each group: With their respective bNIHSS as a reference, the NIHSS scores at the other six time points are compared to obtain their respective p-values. The NIHSS scores of the study group (Table 3) decreased significantly after 12h of treatment (OR = 0.528; 95% CI 0.295–0.948; p = 0.032), and the NIHSS score decreased more significantly after 24h of treatment (OR = 0.381; 95% CI 0.212–0.683; p = 0.001). In the control group (Table 3), only the NIHSS score after 3-weeks of treatment decreased significantly (OR = 0.404, 95% CI 0.193–0.846; p = 0.016). The curve trend chart in Figure 1 shows that compared with the control group, the NIHSS scores of the study group decreased more steeply, suggesting that 7-day DAPT+intensive rosuvastatin quickly relieved the clinical symptoms of patients.

Table 3.

Comparison of the trend of NHISS scores in the two groups within 21 days.

Coefficientp-valueOR95% Confidence Interval
Lower  Upper 
(Intercept)  1.000  0.000  2.718  1.614  4.578 
[study group] * [time = 6]  -3.103  0.000  0.045  0.025  0.081 
[study group] * [time = 5]  -2.793  0.000  0.061  0.034  0.110 
[study group] * [time = 4]  -2.138  0.000  0.118  0.066  0.211 
[study group] * [time = 3]  -1.172  0.000  0.310  0.173  0.555 
[study group] * [time = 2]  -0.966  0.001  0.381  0.212  0.683 
[study group] * [time = 1]  -0.638  0.032a  0.528  0.295  0.948 
[study group] * [time = 0]       
[control group] * [time = 6]  -0.906  0.016b  0.404  0.193  0.846 
[control group] * [time = 5]  -0.537  0.154  0.585  0.279  1.223 
[control group] * [time = 4]  0.060  0.873  1.062  0.508  2.223 
[control group] * [time = 3]  0.376  0.319  1.456  0.696  3.048 
[control group] * [time = 2]  0.262  0.487  1.299  0.621  2.719 
[control group] * [time = 1]  0.215  0.569  1.240  0.592  2.594 
[control group] * [time = 0]       
a

Indicates the NIHSS score of patients after 12h of treatment (T1) in the study group decreased significantly, which was statistically significant compared with bNIHSS (p = 0.032).

b

Indicates that the NIHSS score of the control group decreased significantly after 3 weeks of treatment (T6), which was statistically significant compared with bNIHSS (p = 0.016).

Comparison of recurrent ischemic stroke between the two groups in 90 days

There were 34 (22.82%) patients in the control group and 9 (7.76%) patients in the study group with recurrent stroke events. The Cox proportional hazards model was used to evaluate the recurrence of ischemic stroke events between the two groups. The study group reduced the risk of recurrent cerebral infarction by 65% (Hazard Ratio [HR] 0.350; 95% CI 0.167–0.730, p = 0.005), showing that 7-day DAPT+intensive rosuvastatin could significantly reduce the risk of recurrent stroke for AIS patients within 90 days (Table 4 & Fig. 2).

Table 4.

Comparison of recurrent ischemic stroke between two groups.

Control group (n = 149)Study group (n = 116)HR and 95% CIp-value
Cases (noCases (no
Recurrent ischemic stroke  34  22.82  7.76  0.350 (0.167‒0.730)  0.005 
Bleeding eventsa  10  6.71  7.76  1.076 (0.424‒2.732)  0.878 
a

According to the GUSTO criteria, they were all minor gastrointestinal mucosal bleeding events.

Figure 2.

Comparison of recurrent ischemic stroke between the two groups within 90 days.

(0.13MB).
Comparison of bleeding events between two groups within 90 days

There were 10 (6.71%) subjects in the control group and 9 (7.79%) in the study group with bleeding events, and there was no significant difference between the two groups (HR = 1.076, 95% CI 0.424–2.732, p = 0.878). No cases of cerebral hemorrhage were confirmed by head CT; mild gastrointestinal mucosal bleeding was confirmed by positive occult blood in stool and vomit,12 suggesting that 7-day DAPT+intensive rosuvastatin did not increase the risk of bleeding in patients with AIS (Table 4 & Fig. 3).

Figure 3.

Probability of survival free of bleeding within 90 days.

(0.08MB).
SILI and SAM events

There was no occurrence of increased levels of ALT, AST, LDH, or CK by more than 3 times the upper limit of normal values within 90 days of follow-up. Comparing the levels of ALT, AST, LDH, and CK before and 2 weeks (14 ± 3 days) after treatment in the study group, no statistically significant difference was noted (p > 0.05), suggesting that intensive rosuvastatin rarely induced SILI or SAM (Table 5).

Table 5.

Comparison of ALT, AST, LDH and CK before and 2 weeks after treatment.

ALT (U/L)  AST (U/L)  LDH (U/L)  CK (U/L) 
Before25%  13.830  13.00  150.50  53.25 
Median  18.35  16.55  178.50  70.00 
75%  24.53  21.60  202.50  109.25 
After25%  12.65  14.10  151.00  46.50 
Median  17.20  17.70  171.50  68.00 
75%  25.58  21.85  202.25  101.50 
p (2-tailed)0.251  0.483  0.114  0.086 

ALT, Alanine Transferase; AST, Aspartate Transferase; LDH, Lactate Dehydrogenase; CK, Creatine kinase.

Discussion

Compared with the regimen of SAPT+rosuvastatin, short-term (7-day) DAPT+intensive rosuvastatin was an ideal regimen for mild-to-moderate AIS. Short-term DAPT+intensive rosuvastatin quickly and effectively relieved focal neurological deficits symptoms and significantly reduced the risk of recurrent ischemic stroke in patients with AIS within 90 days ‒ without increasing adverse events such as bleeding, SILI, or SAM. The results should be related to the strong inhibition of platelet aggregation and thrombosis reduction by DAPT, pleiotropy of intensive statins, and an appropriate DAPT course.

Activation and aggregation of platelets are major factors in thrombosis.15 Aspirin is a cyclooxygenase inhibitor, and clopidogrel is an adenosine diphosphate receptor antagonist. They can quickly and effectively inhibit platelet aggregation and platelet release through different ways, thereby reducing thrombosis and promoting thrombolysis. The DAPT with aspirin combined with clopidogrel is a drug recommended by the AIS guidelines,10 which can significantly reduce the risk of recurrent ischemic stroke in AIS patients.16,17 Non-cardiac ischemic stroke is attributed to Atherosclerotic Cardiovascular Disease (ASCVD),18 and the elevated levels of non-HDL-C and LDL-C in the circulation are the fundamental factors of atherosclerosis18-20 and the key to the occurrence of ASCVD events.21,22 Statins reduce endogenous cholesterol synthesis by inhibiting β-hydroxyβ-methylglutaryl-CoA reductase. They also increase non-HDL-C and LDL clearance by promoting the expression of low-density lipoprotein receptors concentrated in hepatocytes,23,24 which is an important means to reduce ASCVD events,25-27 and effectively reduce the risk of recurrent cerebral infarction.28,29 It is a routine drug for acute treatment28,29 and secondary prevention of ischemic stroke.2,30

Statins have other pleiotropic effects such as immunomodulation, improving endothelial function, and antioxidant and antithrombotic effects. By up-regulating Endothelial Nitric Oxide Synthase (eNOS), statins can increase nitric oxide concentration, dilate cerebral blood vessels, increase local cerebral blood flow, and relieve ischemia and hypoxia symptoms;31 Statins can increase blood supply to the ischemic zone by inhibiting thrombosis, promoting thrombolysis, and shrinking vascular plaques.32,33 Statins can reduce the infarct volume by promoting the formation of vascular structure and improving local blood supply;34 Statins exert their anti-inflammatory properties35-37 by inhibiting the release of inflammatory factors and reducing the stress response in the acute phase of ischemia.38 Statins can also improve endothelial function and inhibit apoptosis.39,40 All these effects are dose-dependent.32,41

Previous studies have shown that DAPT increased the occurrence of bleeding events,7-9 but this mainly occurred on the 8th–90th day of DAPT;9 this study limited the therapy regimen to a 7-day course of DAPT to avoid bleeding events. Other studies showed that statins induced liver injury and elevated transaminase.42 However, rosuvastatin is a water-soluble statin, which can only enter the liver cells through specific channel proteins on the liver cell membrane to inhibit cholesterol synthesis. It is not easy to enter other tissues and cells, including striated muscle cells, and hence rosuvastatin rarely leads to side effects such as muscle weakness, soreness, and muscle enzyme elevation.43 This forms the basis of the therapy regimen of 7-day DAPT combined with intensive rosuvastatin.

The limitations of this study include its single-center and incomplete randomized controlled design, and its small sample size. The present results should therefore be interpreted with caution and validated further in future appropriately designed, large-scale studies.

In conclusion, short-term (7-d) DAPT combined with intensive rosuvastatin was a more accurate DAPT regimen for patients with mild-to-moderate AIS, which could rapidly and effectively relieve the clinical symptoms and significantly reduce the risk of recurrent ischemic stroke without increasing adverse events such as bleeding, SILI, or SAM.

Funding

Supported by Beijing Municipal Commission of Science and Technology (Z181100001718066)

Trial Registration: China Clinical Trial Registry, ChiCTR1800017809 (2018-08-15).

Author's contribution

Study conception or design: TZ and HTL; acquisition of the data: TD, JMC, XML, XHY, LSL; analysis and interpretation of the data: TD, WH, HTL; drafting and revising the article: TZ and HTL. All authors read and approved the final manuscript.

All authors approve to submit this manuscript.

References
[1]
Y Qin, X Tong, J Fan, Z Liu, R Zhao, T Zhang, et al.
Global burden and trends in incidence, mortality, and disability of stomach cancer from 1990 to 2017.
Clin Transl Gastroenterol, 12 (2021), pp. e00406
[2]
LD Wang, Report on stroke prevention and treatment in China Writing Group.
Brief report on stroke prevention and treatment in China, 2020.
Chin J Cerebrovasc Dis, 19 (2022), pp. 136-144
[3]
A Morotti, L Poli, P. Costa.
Acute Stroke.
Semin Neurol, 39 (2019), pp. 61-72
[4]
P Yang, Y Zhang, L Zhang, Y Zhang, KM Treurniet, W Chen, et al.
DIRECT-MT Investigators. Endovascular thrombectomy with or without intravenous alteplase in acute stroke.
N Engl J Med, 382 (2020), pp. 1981-1993
[5]
K Suzuki, K Kimura, M Takeuchi, M Morimoto, R Kanazawa, Y Kamiya, et al.
The randomized study of endovascular therapy with versus without intravenous tissue plasminogen activator in acute stroke with ICA and M1 occlusion (SKIP study).
Int J Stroke, 14 (2019), pp. 752-755
[6]
Y Wang, Y Wang, X Zhao, L Liu, D Wang, C Wang, CHANCE Investigators, et al.
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
N Engl J Med., 369 (2013), pp. 11-19
[7]
D Wang, L Gui, Y Dong, H Li, S Li, H Zheng, et al.
Dual antiplatelet therapy may increase the risk of non- intracranial haemorrhage in patients with minor strokes: a subgroup analysis of the CHANCE trial.
Stroke Vasc Neurol, 1 (2016), pp. 29-36
[8]
K Bhatia, V Jain, D Aggarwal, M Vaduganathan, S Arora, Z Hussain, et al.
Dual antiplatelet therapy versus aspirin in patients with stroke or transient ischemic attack: meta-analysis of randomized controlled trials.
Stroke, 52 (2021), pp. e217-e223
[9]
SC Johnston, JD Easton, M Farrant, W Barsan, RA Conwit, JJ Elm, Clinical Research Collaboration, Neurological Emergencies Treatment Trials Network, and the POINT Investigators, et al.
Clopidogrel and aspirin in acute ischemic stroke and high-risk TIA.
N Engl J Med, 379 (2018), pp. 215-225
[10]
Chinese Stroke Society.
Chinese guidelines for diagnosis and treatment of acute ischemic stroke 2018.
Chin J Neurol, 51 (2018), pp. 666-682
[11]
K. Ghandehari.
Challenging comparison of stroke scales.
J Res Med Sci, 18 (2013), pp. 906-910
[12]
GUSTO investigators.
An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction.
N Engl J Med., 329 (1993), pp. 673-682
[13]
Chinese Medical Journals Publishing House.
Guideline for primary care of dyslipidemias (2019).
Chin J Gen Pract, 18 (2019), pp. 406-416
[14]
A. Tournadre.
Statins, myalgia, and rhabdomyolysis.
Joint Bone Spine, 87 (2020), pp. 37-42
[15]
M Koupenova, L Clancy, HA Corkrey, JE. Freedman.
Circulating platelets as mediators of immunity, inflammation, and thrombosis.
Circ res, 122 (2018), pp. 337-351
[16]
F Condello, G Liccardo, G. Ferrante.
Clinical effects of dual antiplatelet therapy or aspirin monotherapy after acute minor ischemic stroke or transient ischemic attack, a meta-analysis.
Curr Pharm Des, 27 (2021), pp. 4140-4146
[17]
J Ringler, M Steck, SP Shah, KW. Chester.
Indications and evidence for dual antiplatelet therapy after acute ischemic stroke.
Crit Care Nurs Q, 43 (2020), pp. 122-137
[18]
NJ Stone, JG Robinson, AH Lichtenstein, CNB Merz, CB Blum, RH Eckel, American College of Cardiology/American Heart Association Task Force on Practice Guidelines, et al.
2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.
J Am Coll Cardiol, 63 (2014), pp. 2889-2934
[19]
H Soran, R Dent, P. Durrington.
Evidence-based goals in LDL-C reduction.
Clin Cardiol, 106 (2017), pp. 237-248
[20]
A Pirillo, F Bonacina, GD Norata, AL. Catapano.
The interplay of lipids, lipoproteins, and immunity in atherosclerosis.
Curr Atheroscler Rep, 20 (2018), pp. 12
[21]
BA Ference, HN Ginsberg, I Graham, KK Ray, CJ Packard, E Bruckert, et al.
Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel.
Eur Heart J, 38 (2017), pp. 2459-2472
[22]
J Borén, MJ Chapman, RM Krauss, CJ Packard, JF Bentzon, CJ Binder, et al.
Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel.
Eur Heart J, 41 (2020), pp. 2313-2330
[23]
SM. Grundy.
Approach to lipoprotein management in 2001 National Cholesterol Guidelines.
Am J Cardiol, 90 (2002), pp. 11i-21i
[24]
SM Grundy, JI Cleeman, CN Merz, HB Brewer Jr, LT Clark, DB Hunninghake, et al.
Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines.
J Am Coll Cardiol, 44 (2004), pp. 720-732
[25]
TA Jacobson, MK Ito, KC Maki, CE Orringer, HE Bays, PH Jones, et al.
National lipid association recommendations for patient-centered management of dyslipidemia: part 1 ‒ full report.
J Clin Lipidol, 9 (2015), pp. 129-169
[26]
WN Kernan, B Ovbiagele, HR Black, DM Bravata, MI Chimowitz, MD Ezekowitz, American Heart Association Stroke Council, Council on Cardiovascular and Stroke Nursing, Council on Clinical Cardiology, and Council on Peripheral Vascular Disease, et al.
Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association.
Stroke., 45 (2014), pp. 2160-2236
[27]
F Mach, C Baigent, AL Catapano, KC Koskinas, M Casula, L Badimon, et al.
2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk.
Eur Heart J, 41 (2020), pp. 111-188
[28]
KS Hong, JS. Lee.
Statins in acute ischemic stroke: a systematic review.
J Stroke, 17 (2015), pp. 282-301
[29]
B Christophe, M Karatela, J Sanchez, J Pucci, ES. Connolly.
Statin therapy in ischemic stroke models: a meta-analysis.
Transl Stroke Res, 11 (2020), pp. 590-600
[30]
WJ Powers, AA Rabinstein, T Ackerson, OM Adeoye, NC Bambakidis, K Becker, et al.
Guidelines for the Early Management of Patients with Acute Ischemic Stroke: 2019 Update to the 2018 Guidelines for the Early Management of Acute Ischemic Stroke: A Guideline for Healthcare Professionals from the American Heart Association/American Stroke Association.
Stroke., 50 (2019), pp. e344-e418
[31]
M Endres, U Laufs, Z Huang, T Nakamura, P Huang, MA Moskowitz, et al.
Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase.
Proc Natl Acad Sci USA., 95 (1998), pp. 8880-8885
[32]
L Räber, M Taniwaki, S Zaugg, H Kelbæk, M Roffi, L Holmvang, IBIS 4 (Integrated Biomarkers and Imaging Study-4) Trial Investigators (NCT00962416), et al.
Effect of high-intensity statin therapy on atherosclerosis in non-infarct-related coronary arteries (IBIS-4): a serial intravascular ultrasonography study.
Eur Heart J., 36 (2015), pp. 490-500
[33]
H Mollazadeh, E Tavana, G Fanni, S Bo, M Banach, M Pirro, et al.
Effects of statins on mitochondrial pathways.
J Cachexia Sarcopenia Muscle, 12 (2021), pp. 237-251
[34]
ZJ Cheng, TM Dai, YY Shen, J-L He, J Li, J-L Tu, et al.
Atorvastatin Pretreatment Attenuates Ischemic Brain Edema by Suppressing Aquaporin 4.
J Stroke Cerebrovasc Dis, 27 (2018), pp. 3247-3255
[35]
S Mohammad, H Nguyen, M Nguyen, M Abdel-Rasoul, V Nguyen, CD Nguyen, et al.
Pleiotropic effects of statins: untapped potential for statin pharmacotherapy.
Curr Vasc Pharmacol, 17 (2019), pp. 239-261
[36]
RS. Duan.
Immune regulation of statins in atherosclerosis and opinions on its clinical applications.
J Shandong Univ (Health Sci.), 53 (2015), pp. 1-4
[37]
K Wu, S Tian, H Zhou, Y. Wu.
Statins protect human endothelial cells from TNF-induced inflammation via ERK5 activation.
Biochem Pharmacol, 85 (2013), pp. 1753-1760
[38]
A Nenna, F Nappi, M Lusini, UM Satriano, D Schilirò, C Cristiano Spadaccio, et al.
Effect of statins on platelet activation and function: from molecular pathways to clinical effects.
Biomed Res Int, 2021 (2021),
[39]
A Vavlukis, M Vavlukis, K Mladenovska, A Dimovski, N Muñoz-García, VS Villaplana, et al.
Antioxidative Effects of Rosuvastatin in Low-to-Moderate Cardiovascular Risk Subjects.
Pril (Makedon Akad Nauk Umet Odd Med Nauki), 43 (2022), pp. 65-75
[40]
SH Lee, HS Shin, I. Oh.
The protective effects of statins towards vessel wall injury caused by a stent retrieving mechanical thrombectomy device: a histological analysis of the rabbit carotid artery model.
J Korean Neurosurg Soc, 64 (2021), pp. 693-704
[41]
C Kilit, FE Koçak, T Paşalı Kilit.
Comparison of the effects of high-dose atorvastatin and high-dose rosuvastatin on oxidative stress in patients with acute myocardial infarction: A pilot study.
Turk Kardiyol Dern Ars, 45 (2017), pp. 235-243
[42]
DN Kiortsis, TD Filippatos, DP Mikhailidis, MS Elisaf, EN. Liberopoulos.
Statin-associated adverse effects beyond muscle and liver toxicity.
[43]
YF. Li.
Research and development of statins and their fat solubility and water solubility.
Chin J Geriatr Heart Brain Vessel Dis, 20 (2018),
Copyright © 2023. HCFMUSP
Descargar PDF
Opciones de artículo
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos